The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few […]
Beta Bionics
The 10 biggest diabetes tech stories from 2023
It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part. Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too. In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no different. […]
Beta Bionics integrates iLet bionic pancreas with Dexcom G7
Beta Bionics announced today that it began the U.S. launch of its iLet bionic pancreas with the Dexcom G7 continuous glucose monitor (CGM). The launch marks the second G7-compatible automated insulin delivery system to hit the market in as many days. Yesterday, Tandem Diabetes Care became the first to launch an artificial pancreas using Dexcom’s […]
Beta Bionics earns pharmacy benefit win for bionic pancreas
Beta Bionics announced that Express Scripts added its iLet bionic pancreas and associated supplies to its commercial national formulary offerings. The decision enables faster and easier access to iLet for eligible users with plans that cover the system under their pharmacy benefit. It marks more good news for Beta Bionics, which closed a $100 million […]
Beta Bionics closes $100M Series D to support bionic pancreas
Beta Bionics announced that it successfully closed a Series D funding round, securing $100 million in new equity capital. Concord, Massachusetts-based Beta Bionics develops its flagship iLet bionic pancreas. The autonomous insulin delivery system streamlines diabetes management and reduces the burden on patients and physicians. iLet received FDA clearance in May. While Beta Bionics did […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
Convatec, Beta Bionics partner on iLet bionic pancreas
Convatec announced that it partnered with Beta Bionics on the launch of the iLet Bionic Pancreas for automated insulin delivery. FDA last week cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software. Convatec offers design and manufacturing services for infusion set technologies and insertion devices for insulin pump treatment. Beta […]
FDA clears automated insulin pump from Beta Bionics for type 1 diabetes
The FDA announced today that it cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software. FDA clearance covers the devices for people 6 years of age and older with type 1 diabetes. Combined with a compatible, FDA-cleared integrated continuous glucose monitor (iCGM), they form the iLet Bionic Pancreas. Using an […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Beta Bionics appoints new CMO as it prepares for artificial pancreas launch
Beta Bionics announced that it appointed Dr. Steven Russell as its chief medical officer (CMO) as it readies itself for a major product launch. Concord, Massachusetts-based Beta Bionics develops the iLet bionic pancreas system. The pocket-sized, wearable, investigational iLet device autonomously doses insulin. Worn like an insulin pump, iLet users only enter body weight to […]
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. According to a news release, […]